Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP

Exclusion Criteria

• •Individuals living with HIV.
• •Individuals assigned female sex at birth will be excluded.
• •Individuals who are currently taking oral PrEP from another source and are not willing to switch to lenacapavir for PrEP for the duration of the study will also be excluded.
• •Individuals who report a history of severe renal or hepatic disease or with clinical stigmata of either disease on physical exam as assessed by a study clinician will be excluded.
• •Individuals taking a medication with a significant interaction with lenacapavir will be excluded from the study.